clear

Current Filters

Showing 1 - 10 results of 1046

tafamidis (Vyndaqel) (Last Updated: Mar 23, 2021)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Vyndaqel
Manufacturer:
Pfizer Canada
Submission Type:
Initial
Indications:

Treatment of adult patients with
cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or
hereditary, to reduce cardiovascular
mortality and cardiovascular-related hospitalization.

upadacitinib (Rinvoq) (Last Updated: Apr 1, 2020)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Rinvoq
Manufacturer:
AbbVie
Submission Type:
Initial
Indications:

Arthritis, Rheumatoid

Iron (III) Isomaltoside 1000 (Monoferric) (Last Updated: May 19, 2020)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Monoferric
Manufacturer:
Pharmacosmos A/S
Submission Type:
Initial
Indications:

iron deficiency anemia

Demylocan for Myelodysplastic Syndromes – Details (Demylocan) (Last Updated: May 29, 2019)

Project Line:
Reimbursement Review
Project Status:
Not filed
Contains:
Brand Name Manufacturer Submission Type Indication

Brand Name:
Demylocan
Manufacturer:
Pharmascience Inc.
Submission Type:
Non-Submission

esketamine hydrochloride (Spravato) (Last Updated: Apr 30, 2021)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Spravato
Manufacturer:
Janssen Inc.
Submission Type:
Initial
Indications:

Indicated in combination with a SSRI or SNRI, for the treatment of major depressive disorder in adults who have not responded adequately to at least two separate courses of treatment with different antidepressants, each of adequate dose and duration, in the current moderate to severe depressive episode.

Download results as CSV